372 related articles for article (PubMed ID: 21430363)
21. LRRK2 in Parkinson's disease: function in cells and neurodegeneration.
Webber PJ; West AB
FEBS J; 2009 Nov; 276(22):6436-44. PubMed ID: 19804415
[TBL] [Abstract][Full Text] [Related]
22. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
23. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease.
Bardien S; Lesage S; Brice A; Carr J
Parkinsonism Relat Disord; 2011 Aug; 17(7):501-8. PubMed ID: 21641266
[TBL] [Abstract][Full Text] [Related]
24. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
[TBL] [Abstract][Full Text] [Related]
25. LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles.
Yue Z
FEBS J; 2009 Nov; 276(22):6445-54. PubMed ID: 19804414
[TBL] [Abstract][Full Text] [Related]
26. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration.
Smith WW; Pei Z; Jiang H; Moore DJ; Liang Y; West AB; Dawson VL; Dawson TM; Ross CA
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18676-81. PubMed ID: 16352719
[TBL] [Abstract][Full Text] [Related]
27. Novel insights into the neurobiology underlying LRRK2-linked Parkinson's disease.
Gómez-Suaga P; Fdez E; Fernández B; Martínez-Salvador M; Blanca Ramírez M; Madero-Pérez J; Rivero-Ríos P; Fuentes JM; Hilfiker S
Neuropharmacology; 2014 Oct; 85():45-56. PubMed ID: 24863040
[TBL] [Abstract][Full Text] [Related]
28. LRRK2 signaling pathways: the key to unlocking neurodegeneration?
Berwick DC; Harvey K
Trends Cell Biol; 2011 May; 21(5):257-65. PubMed ID: 21306901
[TBL] [Abstract][Full Text] [Related]
29. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
30. Identification of three novel LRRK2 mutations associated with Parkinson's disease in a Calabrian population.
Anfossi M; Colao R; Gallo M; Bernardi L; Conidi ME; Frangipane F; Vasso F; Puccio G; Clodomiro A; Mirabelli M; Curcio SA; Torchia G; Smirne N; Di Lorenzo R; Maletta R; Bruni AC
J Alzheimers Dis; 2014; 38(2):351-7. PubMed ID: 23963289
[TBL] [Abstract][Full Text] [Related]
31. Mutations in LRRK2 as a cause of Parkinson's disease.
Giasson BI; Van Deerlin VM
Neurosignals; 2008; 16(1):99-105. PubMed ID: 18097165
[TBL] [Abstract][Full Text] [Related]
32. LRRK2 Parkinson's disease: from animal models to cellular mechanisms.
Lin CH; Tsai PI; Wu RM; Chien CT
Rev Neurosci; 2011; 22(4):411-8. PubMed ID: 21679126
[TBL] [Abstract][Full Text] [Related]
33. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
34. Kinase signaling dysfunction in Parkinson's disease: a reverse genetic approach in Drosophila.
Huang Y; Shenoy S; Lu B; Liu W; Li C
J Neurogenet; 2012 Jun; 26(2):158-67. PubMed ID: 22486164
[TBL] [Abstract][Full Text] [Related]
35. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
36. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease.
Liu J; Zhou Y; Wang C; Wang T; Zheng Z; Chan P
Parkinsonism Relat Disord; 2012 Feb; 18(2):140-3. PubMed ID: 21924942
[TBL] [Abstract][Full Text] [Related]
37. LRRK2 pathobiology in Parkinson's disease.
Martin I; Kim JW; Dawson VL; Dawson TM
J Neurochem; 2014 Dec; 131(5):554-65. PubMed ID: 25251388
[TBL] [Abstract][Full Text] [Related]
38. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
39. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
Xiong Y; Dawson VL; Dawson TM
Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
[TBL] [Abstract][Full Text] [Related]
40. Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Floris G; Cannas A; Solla P; Murru MR; Tranquilli S; Corongiu D; Rolesu M; Cuccu S; Sardu C; Marrosu F; Marrosu MG
Parkinsonism Relat Disord; 2009 May; 15(4):277-80. PubMed ID: 18805725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
